Keros Therapeutics Has Closed Screening For The TROPOS Trial, A Phase 2 Clinical Trial Of Cibotercept In Combination With Background Therapy In Patients With Pulmonary Arterial Hypertension
Portfolio Pulse from Benzinga Newsdesk
Keros Therapeutics has closed screening for its Phase 2 TROPOS trial of cibotercept in patients with pulmonary arterial hypertension, expecting to complete enrollment by September and present data in Q2 2025.
September 03, 2024 | 12:24 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Keros Therapeutics has closed screening for its Phase 2 TROPOS trial of cibotercept in patients with pulmonary arterial hypertension, expecting to complete enrollment by September and present data in Q2 2025.
The closing of screening for the TROPOS trial indicates progress in Keros' clinical development pipeline, which is a positive signal for investors. The expectation to complete enrollment by September and present data in Q2 2025 suggests a clear timeline for potential advancements, likely boosting investor confidence and positively impacting the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100